Smol International Releases 2022 Half-Year Performance Report

Aug.24.2022
Smol International Releases 2022 Half-Year Performance Report
Semiconductor company SMIC reported solid H1 2022 earnings of CNY 56.5 billion, driven by innovation and diversification.

On August 24th, Semiconductors International (06969) released its financial report for the first half of 2022. The company reported a revenue of RMB 5.65 billion and an adjusted net profit of RMB 1.44 billion.


In the first half of 2022, Chen Zhiping, Chairman of the Board of Directors of Sumitomo International, expressed the company's commitment to long-term thinking in the face of an ever-changing and challenging external environment. The company will continue to invest in the future and adhere to its long-term philosophy. Scientific and technological innovation is the driving force of Sumitomo's development, and only by adhering to innovation can the company build long-term competitiveness and create long-term value for the country, customers, employees, and shareholders.


The US market helps clients become number one, while the Chinese market actively supports regulation.


The financial report reveals that from January to June 2022, Simore's operating income was 5.65 billion and adjusted net profit was 1.44 billion.


Behind the stable revenue is SMOORE's active layout in the electronic atomization market and the diversity of its income distribution. According to data, in the first half of the year, SMOORE's enterprise customer business (ODM) and retail customer business (APV) grew rapidly in Europe. In terms of revenue for the first half of the year, the proportion of income from countries and regions outside of China and the United States was 39%, an increase of 16 percentage points compared to the same period last year, which was 23%.


In the US market, Smoore, with its technological and manufacturing advantages, has become a leading manufacturer of ENDS (electronic nicotine delivery systems) that assists many customers to pass PMTA (premarket tobacco product application). Additionally, Smoore has helped its customers gain market share by offering reasonable prices. It is expected that the company will maintain stable and healthy orders throughout the second half of the year.


In the Chinese market, Smoore supports regulatory policies. The current planning and regulation by the National Tobacco Monopoly Administration marks a new starting point for industry development in accordance with regulations. Smoore strictly adheres to regulatory requirements and actively applies for tobacco monopoly production licenses. Currently, three subsidiaries have already been granted production licenses. Smoore will continue to strengthen research and development of products that meet national standards to meet regulatory requirements and provide consumers with a better experience. At the same time, it will ensure the delivery of products that meet national standards from the manufacturing end.


Research and development investment has increased significantly by 156%, as the company continues to focus on internal innovation to build its core competitiveness.


Chen Zhiping stated that on the path of creating a globally leading atomization technology platform, it is impossible to have a completely smooth journey. We will continue to believe in the promising future of atomization technology, persist in invention and innovation, and remain committed to a long-term strategy.


As a result, SiMoEr has been increasing their research and development investment according to their planned schedule. They are focusing particularly on areas such as basic research, new materials research, and atomization medical treatment in order to improve their talent density, establish a global research and development system, and build their core competitiveness. In the first half of the year, their research and development expense was 604 million yuan, which is a 156% increase compared to the same period last year.


During the first half of the year, 14 basic research institutes were put into operation globally, with several important scientists and hundreds of masters and doctoral students from renowned universities joining the company. As of June 30th, there were 1,472 R&D experts at SMIC, accounting for over 40% of the total R&D personnel.


Top talent joining has enabled Semler to further cultivate core technology and build a core patent barrier. Currently, there are 4,337 patent applications globally, with 929 newly added applications in the first half of this year. In April of this year, "Semler's launch of a 337 rights protection investigation in the US" was consecutively selected as one of the top ten intellectual property events in Guangdong Province and Shenzhen City in 2021.


Medical atomization products smoothly enter domestic approval channel.


In the field of medical nebulization, Simoer has established a wholly-owned subsidiary in the United States to focus on the research and development of respiratory drug products, providing relief for patients with asthma and chronic obstructive pulmonary disease. Currently, they have reached an agreement with one of the world's largest pharmaceutical manufacturing companies to develop two nebulized drugs. If the products are approved smoothly, they are expected to be launched in the next few years.


In addition, Simoer's first domestic research and development of a nebulizer device is currently going through the approval process in China.


In the first half of the year, exports generated 3.955 billion yuan in foreign exchange earnings. The four major directions for reducing carbon emissions were announced as a priority.


As a "dream chaser with love", Si Moer continuously responds to public expectations and practices corporate social responsibility through concrete actions.


In the first half of the year, SMIC generated 3.955 billion USD in foreign exchange earnings by exporting to overseas markets. To address the challenging situation of over 10 million university graduates in 2022, SMIC has established deep school-enterprise cooperation relationships with 15 colleges and universities, cultivating and supplying over 1,000 skilled workers to the industry. Additionally, SMIC is actively implementing talent management programs, such as "SMIC model talent" and "SMIC skilled talent," targeting graduates in 2022 and 2023.


In addition, as the first vaporization technology company to list a carbon neutrality schedule, Simoer has released its carbon reduction targets and plans to achieve carbon neutrality within scopes 1 and 2 by 2050. Data shows that in 2021, Simoer has achieved a year-on-year decrease in greenhouse gas emissions density of about 16% and a year-on-year reduction in water consumption density of about 9.4%.


During the first half of the year, semiconductor company SMIC was able to maintain its A-grade rating in ESG evaluations published by MSCI, the world's largest index provider. Additionally, SMIC was awarded five major prizes, including the award for corporate governance (ESG), in the 2022 Asia Management Team selection.


This article includes excerpts or reprints of information from third-party sources. Copyright belongs to the original media and authors. If there is any infringement, please contact us for deletion. Any organization or individual who wishes to reprint must contact the author. Please do not directly repost.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Japanese Addiction Psychiatrist Says Complete Abstinence Is Not Always the Goal of Harm Reduction | 2Firsts Interview
Japanese Addiction Psychiatrist Says Complete Abstinence Is Not Always the Goal of Harm Reduction | 2Firsts Interview
Complete abstinence is not always the goal of addiction treatment under a harm-reduction approach, Japanese psychiatrist Tomohiro Shirasaka told 2Firsts in Manila. In the interview, he discussed patients' quality of life, Japan's shift towards heated tobacco products, and the challenges of quitting smoking for people with mental illness. Drawing on addiction treatment work in the Philippines, he advocated support rather than punishment and questioned whether fear-based health warnings effectively address the reasons people continue smoking.
Nov.10
Pennsylvania Lists 163 Vape Products Eligible for Sale, Including Vuse and JUUL; Previously Pending Chinese Brands Such as OXBAR Remain Absent, While Unlisted Products Including Geek Bar Face Enforcement From October 19
Pennsylvania Lists 163 Vape Products Eligible for Sale, Including Vuse and JUUL; Previously Pending Chinese Brands Such as OXBAR Remain Absent, While Unlisted Products Including Geek Bar Face Enforcement From October 19
Pennsylvania begins enforcing its electronic nicotine delivery system (ENDS) directory restrictions on October 19, 2026. The October 18 directory contained 163 product records from seven manufacturers, including Vuse, JUUL, NJOY, Logic and Naked 100. Geek Bar, RAZ and Lost Mary were absent. BAT, Altria, Japan Tobacco and JUUL collectively accounted for 112 records, or 68.7%, while Imperial Brands' blu had no listings. The directory included 15 disposable vape records, 40 bottled e-liquids and 10 products labeled 0mg, but no open-system refillable devices. Twenty-two manufacturer certifications remained under review. Four Logic models corresponding to Smoore's pending records were listed under the brand owner, while LYCO, OXBAR and Boulder/Rock had no approved directory entries.
Regulations
Oct.19
Virginia Tobacco Retail Permit Takes Effect October 1, Covering Vapes as More Than 3,000 Businesses Apply in September
Virginia Tobacco Retail Permit Takes Effect October 1, Covering Vapes as More Than 3,000 Businesses Apply in September
Virginia's new retail tobacco permit system took effect October 1, requiring sellers of vapes, nicotine products and related devices and accessories to obtain a Retail Tobacco Permit for each business location. Virginia ABC said more than 3,000 businesses applied in September alone, creating a processing backlog. Qualifying applicants that filed before October 1 may temporarily operate under a Letter of Authorization. The new store-level permit also sits alongside Virginia's existing vape product directory, where sales of unlisted liquid nicotine or nicotine vapor products can trigger civil penalties starting at $5,000.
Regulations
Oct.03
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
American Vapor Manufacturers (AVM) and Altria subsidiaries Helix Innovations and NJOY filed separate motions on October 7, 2026, seeking to intervene on the FDA's side in a lawsuit challenging its enforcement guidance for certain e-cigarette and nicotine pouch products with pending premarket tobacco product applications (PMTAs). Seven public health and tobacco-control organizations, including the Campaign for Tobacco-Free Kids, sued the agency in July to overturn the policy. AVM argues that vacating the guidance could disrupt orders, inventory, retail distribution and investments in regulatory submissions.
Regulations
Oct.09
Special Report|Japan Tobacco Buys CLEW: Can Its 160,000-Store Cigarette Network Help It Vie for U.S. Nicotine Pouch Share Against PMI and BAT?
Special Report|Japan Tobacco Buys CLEW: Can Its 160,000-Store Cigarette Network Help It Vie for U.S. Nicotine Pouch Share Against PMI and BAT?
Japan Tobacco Inc. (JT) announced on November 12, 2026, that it had acquired the U.S. assets of nicotine pouch brand CLEW from Nevcore Innovations Inc., including trademarks, intellectual property, product formulations and a Premarket Tobacco Product Application (PMTA). CLEW, currently distributed through selected outlets in 13 U.S. states, will immediately join the JTI LIGGETT portfolio. The transaction follows JT's approximately $2.4 billion acquisition of U.S. cigarette maker Vector Group in 2024. JTI LIGGETT says its existing cigarette brands reach more than 160,000 U.S. retail stores. During the 2026 NACS Show in October, JTI LIGGETT booth staff told 2Firsts that the company had not yet launched nicotine pouches in the United States. Although Nevcore previously announced FDA acceptance of CLEW's PMTA, the brand is absent from the agency's current list of authorized nicotine pouch products. JT has not disclosed a retail expansion plan for CLEW.
Business
Nov.12
2Firsts Hosts China Market Forum at InterTabac as Global Industry Attention to China’s Tobacco Sector Deepens
2Firsts Hosts China Market Forum at InterTabac as Global Industry Attention to China’s Tobacco Sector Deepens
On September 16, 2Firsts hosted a China-focused industry forum during InterTabac in Dortmund, bringing together more than 30 participants from North America, Europe, India, South Korea and other markets. The session covered traditional tobacco, next-generation products, exports, technology, regulation and supply chains, while examining how China’s tobacco sector operates, where its transformation may be heading, and why its growing role matters increasingly to companies across the global tobacco and nicotine industry.
Sep.21